In COPD patients, increased levels of IL33 in serum correlate with a higher risk of exacerbations, and higher IL-33 expression in lung tissue correlates with disease severity [53,68] and triggers sustained immune responses causing alveolar epithelial cell damage, which makes the idea of targeting IL-33 by using antibody-mediated blockades [77,78,79] attractive. The gene discussed is IL33; the disease is chronic obstructive pulmonary disease.